KTTA — what changed in the latest 10-Q

Text added vs the prior filing · source: 10-Q · 2026-08-14

• Our lead product candidate, PAS-004, is a next-generation oral once-daily macrocyclic mitogen-activated protein kinase, or MEK inhibitor being developed for the long-term treatment of chronic diseases, including the neurocutaneous manifestations of neurofibromatosis type 1 (“NF1“). Following the U.S…

• Our initial planned indication for FDA and other regulatory approval is symptomatic and inoperable NF1-PN in adult and pediatric patients, and it aims to conduct a pediatric Phase 1 trial and registrational trials in both populations.

• General and administrative expenses increased by approximately $365,000, or 22.0%, for the three months ended June 30, 2026 compared to the three months ended June 30, 2025. The increase was primarily driven by increases in (i) insurance expenses of $205,000, (ii) non-cash stock-based expense of app…

• General and administrative expenses increased by approximately $349,000, or 9.7%, for the six months ended June 30, 2026 compared to the six months ended June 30, 2025. The increase was primarily driven by increases in (i) personnel and board expenses of approximately $285,000, (ii) non-cash stock-b…

• We expect general and administrative expenses to continue to decrease slightly in fiscal year 2026 as compared to fiscal year 2025 primarily due to a decrease in impairment expenses offset by a ramp up in operational activity, public company and corporate communications expenses, and non-cash stock-…

Text removed vs the prior filing · source: 10-Q · 2026-05-15

• Our primary operations (the “Therapeutics” segment) are focused on developing our lead product candidate, PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor that we believe may address the limitations and liabilities associated with existing drugs targeting a s…

• The initial indication we plan to seek FDA marketing approval for PAS-004 is the treatment of symptomatic PNs in both adult and pediatric patients with NF1. As such, we aim to conduct a Phase 1 trial for pediatric NF1-PN patients and ultimately complete registrational clinical trials in both adult a…

• General and administrative expenses decreased by approximately $16,000, or 0.8%, for the three months ended March 31, 2026, compared to the three months ended March 31, 2025. The decrease was primarily driven by (i) a decrease in income tax expenses and tax credits of approximately $165,000, (ii) a …

• We expect general and administrative expenses to continue to decrease in fiscal year 2026 as compared to fiscal year 2025 primarily due to a decrease in impairment expenses offset by a ramp up in operational activity, public company and corporate communications expenses, and non-cash stock-based com…

• Research and development expenses relate to activities primarily focused on the development of PAS-004 for the three months ended March 31, 2026 and 2025.